Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder

The FDA has approved ganaxolone (Ztalmy – Marinus) for oral treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients ≥2 years old. It is the first drug to be approved in the US for this indication.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2024-08-15
DOI
https://doi.org/10.58347/tml.2024.1709g
Primary Topic
Genetics and Neurodevelopmental Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Genetics and Neurodevelopmental Disorders
article

Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder

article en

Abstract

The FDA has approved ganaxolone (Ztalmy – Marinus) for oral treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients ≥2 years old. It is the first drug to be approved in the US for this indication.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 66(1709)
Openalex Percentile: Top 85%
Genetics and Neurodevelopmental Disorders
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2024) | TGRS Research Map | TGRS